Timothy Aungst is an Associate Professor of Pharmacy Practice, and clinical pharmacist in home health care. He is passionate about the role of digital health and is a recognized subject matter expert. He has been involved in multiple working groups and advisory roles across biopharma and, startups and curates a blog called “The Digital Apothecary” where he writes about how digital health is transforming pharmacy and healthcare.View full faculty here
Starring: Timothy Aungst i
Hosted by: Illaria Coppola
As our LinkedIn homepages get more and more crowded with news on “Digital Health” and we witness what is unanimously thought of as a revolution in the healthcare space, we find ourselves in need of pausing for a second and looking for a framework to structure our thinking around the complexity of this phenomenon as well as the diversity of its manifestations. Labile definitions, new stakeholders and an unprecedented speed of development make this field a young, yet incredibly ripe one. In the first of our three-part series on Digital Health, Professor Tim Aungst shares his opinions on what digital health means today and will mean tomorrow, what are the greatest sources of opportunity from a TA perspective and tries to define the concept of digital success.
Mike Pace has carved strong expertise in the intersection of digital and healthcare, and formed and led the trailblazing Market Access, Health Economics and Real World Evidence team at prescription digital therapeutics pioneer, Pear Therapeutics, from May 2019 until March 2021. Prior to joining Pear, he was SVP & Divisional Principal at ICON plc, and held Chief Commercial Advisor and Business Development VP roles in digital health companies including OM1 and Beansprout Networks (acquired by IQVIA). Mike also led sales, marketing, training & leadership development and managed markets functions during his tenure with specialty and primary care biopharmaceutical leaders EMD Serono, Allergan and Sanofi. Mike has orchestrated many dozens of outcomes and value-based payer arrangements between digital health, biopharma, payer and technology value chain stakeholders, including pioneering the first outcomes-based agreements for a specialty biologic with a health plan (Cigna) and with a PBM (Prime Therapeutics) in the United States.View full faculty here
Starring: Mike Pace i
Hosted by: Gala Farooq
With pharma companies universally seeking to incorporate digital optimisations throughout the product and patient journey, the industry has adopted some specific strategies to ensure success. In the second of our three-part series on Digital Health, industry veteran Michael Pace discusses what digital transformation brings to the standard operating protocol in pharma, which tangible factors are critical for success in the digital sphere, and how the industry is likely to change in response to the long-term changes brought about by Covid-19.
Marco Rauland is currently the Vice President of Global Market Access & Pricing Strategic Planning at Merck KGaA. Marco has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharma industry, having previously held positions such as VP Europe Market Access at GfK, and global senior leadership roles at Genactis and TNS Healthcare. Marco’s expertise spans therapeutics areas and markets, with his passion and knowledge being shared often through the Pharma Boardroom and Global congresses.View full faculty here
Starring: Marco Rauland i
Hosted by: Nikoletta Gkatza
With regulatory approval and market access being the “gate keepers” between patients and medicines, and also often one of the most cumbersome processes in our industry, there is a strong necessity for solutions that make this process more efficient and robust. Digital tools show great potential to deliver on this need yet come with many considerations and challenges. In the last of our three-part series on Digital Health, Marco Rauland shares his current view on where digital fits across the Market Access value chain, how digital solutions can add value to stakeholders involved in access discussions and key considerations for a future in which access is likely to be driven by smart algorithms.
At Eradigm, we’ve partnered with big and small pioneering companies to help understand and address diverse commercial challenges in digital. Our experience stretches across a whole range of challenges from operations to therapeutics and sales. We have detailed understanding of the technologies, their implementation and the underlying management challenges these bring. We are passionate about helping our clients deconstruct and reassemble a digital strategy anywhere in the ir lifecycle.
We work with stakeholders across the value chain, including market intelligence, market access, commercial teams and senior leadership, to inform and enable strategic decisions.
Our work mostly falls into three distinct yet complementary core areas: competitive intelligence, market access and commercial strategy, including…
Competitive intelligence – competitor strategic benchmarking, CI monitoring, deep dive competitor analysis, competitive landscaping
Market access – pricing and reimbursement assessment, competitor benchmarking, product launch planning, value dossiers, lifecycle management
Commercial strategy – asset strategy, portfolio strategy, corporate strategy, opportunity assessments, technology assessments, strategic workshops
To build the full picture, we combine comprehensive secondary research with primary insights from our global expert network, giving us access to over 300 vetted cell and gene therapy sources including leading physicians, payers and KOLs across the US, EU and APAC, and counting.